CBD-OS

Phase 1Small molecule

Jazz Pharmaceuticals

CBD-OS is one of 10 small molecule programs targeting Focal-onset seizure. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Focal-Onset SeizureActive, not recruiting

Focal-Onset SeizurePhase 1

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Focal-Onset Seizure

#DrugCompanyPhaseTrials

Keppra

Briviact

Zonegran

AAzurity Pharmaceuticals

Approved

—4

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—5

Fycompa

CCatalyst Biosciences

Approved

—6

Neurontin

VViatris Specialty LLC

Depakote

XEN1101

XXenon Pharmaceuticals Inc.

Phase 3

2 9

Padsevonil

UCB

Phase 2

3 10

CBD-OS

Jazz Pharmaceuticals

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Focal-Onset Seizure

NCT07233239

Clinical

Trials by Indication[1]

Focal-onset seizure1 trial

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

Recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 1·NCT07233239·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CBD-OS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CBD-OS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CBD-OS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Jazz Pharmaceuticals

CBD-OS

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Focal-onset seizure1 trial

References

Drug Info

Quick Facts

Related News